Skip to main content
SpringerLink
Log in

Apports de la biologie dans le diagnostic des démences

Biomarkers in differential diagnosis of dementia

  • Dossier
  • Revue
  • Published:
Bio Tribune Magazine

Résumé

Le dosage combiné de trois biomarqueurs dans le liquide céphalorachidien a été établi en 2007 comme une composante essentielle à l’aide au diagnostic de la maladie d’Alzheimer. Ces biomarqueurs: la protéine tau, sa forme phosphorylée P-tau et les peptides amyloïdes sont altérés de manière précoce au cours de la maladie d’Alzheimer, mais restent insuffisants pour le diagnostic différentiel des autres démences. Les perspectives se portent donc sur le développement de nouveaux marqueurs permettant de différencier les démences et l’identification de biomarqueurs plasmatiques.

Abstract

Since 2007, the combined dosage of three biomarkers in the cerebrospinal fluid has been considered an essential component of procedures to help establish a diagnosis of Alzheimer’s disease (AD). These biomarkers include total-Tau proteins, phosphorylated variants of Tau and amyloid-beta peptides. Their levels are altered early during the course of AD but they are not useful for a differential diagnosis of other dementing disorders. Perspectives therefore focus on finding plasmatic biomarkers and developing new biomarkers that would aid discrimination between dementing disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

/+/ Références

  1. Dubois B, Feldman HH, Jacova C, et al. (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8): 734–46

    Article  PubMed  Google Scholar 

  2. Suh YH, Checler F (2002) Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer’s disease. Pharmacol Rev 54(3): 469–525

    Article  PubMed  CAS  Google Scholar 

  3. Delacourte A, Sergeant N, Champain D, et al. (2002) Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease. Neurology 59(3): 398–407

    Article  PubMed  CAS  Google Scholar 

  4. Sergeant N, Delacourte A, Buée L (2005) Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta 1739(2–3): 79–97

    Google Scholar 

  5. Sergeant N, Bretteville A, Hamdane M (2008) Biochemistry of microtubule-associated Tau in Alzheimer’s disease and associated neurological disorders. Expert Rev Proteomics 5(2): 207–24

    Article  PubMed  CAS  Google Scholar 

  6. Zougman A, Pilch B, Podtelejnikov A, et al. (2008) Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 7(1): 386–99

    Article  PubMed  CAS  Google Scholar 

  7. Banks RE, Stanley AJ, Cairns DA, et al. (2005) Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 51(9): 1637–49

    Article  PubMed  CAS  Google Scholar 

  8. Andreasen N, Minthon L, Davidsson P et al. (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58(3): 373–9

    Article  PubMed  CAS  Google Scholar 

  9. Zemlan FP, Mulchahey JJ, Gudelsky GA (2003) Quantification and localization of kainic acid-induced neurotoxicity employing a new biomarker of cell death: cleaved microtubule-associated protein-tau (C-tau). Neuroscience 121(2): 399–409

    Article  PubMed  CAS  Google Scholar 

  10. Johnson GV, Seubert P, Cox TM et al. (1997) The tau protein in human cerebrospinal fluid in Alzheimer’s disease consists of proteolytically derived fragments. J Neurochem 68(1): 430–3

    Article  PubMed  CAS  Google Scholar 

  11. Sjogren M, Davidsson P, Gottfries J et al. (2001) The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer’s disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord 12(4): 257–64

    Article  PubMed  CAS  Google Scholar 

  12. Borroni B, Gardoni F, Parnetti L et al. (2007) Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging (Epub ahead of print)

  13. Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRX 1(2): 213–25

    Article  PubMed  Google Scholar 

  14. Hampel H, Buerger K, Zinkowski R, et al. (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 61(1): 95–102

    Article  PubMed  CAS  Google Scholar 

  15. Vanderstichele H, Van Kerschaver E, Hesse C, et al. (2000) Standardization of measurement of beta-amyloid (1–42) in cerebrospinal fluid and plasma. Amyloid: 245–58

  16. Graff-Radford NR, Crook JE, Lucas J, et al. (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64(3): 354–62. Erratum in: Arch Neurol 64(9): 1246

    Article  PubMed  Google Scholar 

  17. Hansson O, Zetterberg H, Buchhave P, et al. (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3): 228–34

    Article  PubMed  CAS  Google Scholar 

  18. Parnetti L, Lanari A, Silvestrelli G, et al. (2006) Diagnosing prodromal Alzheimer’s disease: role of CSF biochemical markers. Mech Ageing Dev 127(2): 129–32

    Article  PubMed  CAS  Google Scholar 

  19. Buerger K, Otto M, Teipel SJ, et al. (2006) Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging 27(1): 10–5

    Article  PubMed  CAS  Google Scholar 

  20. Collins S, Boyd A, Fletcher A, et al. (2000) Creutzfeldt-Jakob disease: diagnostic utility of 14-3-3 protein immunodetection in cerebrospinal fluid. J Clin Neurosci 7(3): 203–8

    Article  PubMed  CAS  Google Scholar 

  21. Bibl M, Mollenhauer B, Wolf S, et al. (2007) Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations. J Neural Transm 114(5): 621–8

    Article  PubMed  CAS  Google Scholar 

  22. Wiltfang J, Esselmann H, Smirnov A, et al. (2003) Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol 54(2): 263–7

    Article  PubMed  CAS  Google Scholar 

  23. Bibl M, Mollenhauer B, Esselmann H, et al. (2006) CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies. J Neural Transm 113(11): 1771–8

    Article  PubMed  CAS  Google Scholar 

  24. Ingelson M, Blomberg M, Benedikz E, et al. (1999) Tau immunoreactivity detected in human plasma, but no obvious increase in dementia. Dement Geriatr Cogn Disord 10(6): 442–5

    Article  PubMed  CAS  Google Scholar 

  25. van Oijen M, Hofman A, Soares HD, et al. (2006) Plasma Abeta(1–40) and Abeta (1–42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5(8): 655–60

    Article  PubMed  Google Scholar 

  26. Jia JP, Meng R, Sun YX et al. (2005) Cerebrospinal fluid tau, Abeta1–42 and inflammatory cytokines in patients with Alzheimer’s disease and vascular dementia. Neurosci Lett 383(1–2): 12–6

    Article  PubMed  CAS  Google Scholar 

  27. Olsson A, Vanderstichele H, Andreasen N et al. (2005) Simultaneous measurement of beta-amyloid(1–42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51(2): 336–4

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inserm U837, 59000, Lille, France

    S. Schraen-Maschke, N. Sergeant, B. Sablonnière, L. Buée & J. -P. Aubert

  2. Unité fonctionnelle de neurobiologie, pôle de biochimie, CHU de Lille, 59000, Lille, France

    S. Schraen-Maschke, C. Marzys & B. Sablonnière

  3. Université de Lille 2, 59000, Lille, France

    S. Schraen-Maschke, N. Sergeant, F. Pasquier, B. Sablonnière & L. Buée

  4. Centre Mémoire de ressources et de recherche, EA2961, CHU de Lille, 59000, Lille, France

    S. Bombois, C. Crinquette & F. Pasquier

Authors
  1. S. Schraen-Maschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Sergeant
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Marzys
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Bombois
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Crinquette
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Pasquier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Sablonnière
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. Buée
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. -P. Aubert
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schraen-Maschke, S., Sergeant, N., Marzys, C. et al. Apports de la biologie dans le diagnostic des démences. Bio trib. mag. 28, 29–33 (2008). https://doi.org/10.1007/BF03001643

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03001643

Mots clés

Keywords

Search

Navigation